Drug therapy for bone metastasis of malignant tumor: theory, progress, and potential

• Published in: Neoplasma Vol. 69; no. 3; p. 504
• Main Authors: Tian, Ji-Zheng, Ma, Ni-Na, Li, Xiao, Shang, Kun, Cao, Bang-Wei
• Format: Journal Article
• Language: English
• Published: Slovakia 01.01.2022
• Subjects: Bone Neoplasms - secondary; Denosumab - therapeutic use; Diphosphonates - therapeutic use; Humans; Tumor Microenvironment
• ISSN: 0028-2685
• DOI: 10.4149/neo_2021_211006N1412

Bone is a common metastatic site of malignancies, caused by the complex interaction between tumor cells and the bone microenvironment. The complicated procedure covers multiple targets for therapeutic strategies against bone metastasis. At the present, only bisphosphonates and denosumab are currently approved for the prevention of skeletal-related events. But it is still ineffective for some patients, and none of them are proven to prolong the overall survival of patients with bone metastasis. Thus, new bone-modifying agents and therapeutic strategies are required. The review aimed to generalize the basic theory of bone metastasis and major put emphasis on the development of fundamental and potential target drugs in the behavior of bone metastasis. The summary of the drug development process helps to provide ideas for finding new and effective treatments for bone metastasis.